The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Ricks said, displaying a chart that showed ... compounded tirzepatide by mid-March. Investors seemed only somewhat convinced by Ricks’s reassurances. The stock was up 1.2% early Wednesday ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The long answer along with a dosage chart you can find below ... them gave the best results [8]. Tirzepatide, sold as Mounjaro and Zepbound, is another GLP-1 agonist and a GIP agonist, too.

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...